Lymphatic malformations (LMs) are one of the more commonly encountered cystic head-and-neck tumors. Surgical excision is the traditional treatment with inherent perioperative risks. Alternative treatment of these tumors using percutaneous sclerotherapy agents has been proposed with no major consensus on the treatment approaches and sclerotherapy agent choices. This paper presents a systematic review of percutaneous ethanol sclerotherapy for neck lymphangioma and a case report of ethanol ablation in a patient with neck lymphangioma with good cosmesis results. Systematic review was conducted on PubMed using key words: “Ethanol” OR “Alcohol” AND “Ablation” OR “Sclerotherapy” OR “Sclerosing” AND “Lymphangioma” OR “Lymphatic Malformation” as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Three hundred fifteen articles from initial PubMed search results were screened by titles and abstracts. Full text was retrieved. 3 studies were included in our systematic review. Overall evidence quality is modest with marked heterogeneity. All 12 patients treated with percutaneous ethanol sclerotherapy for head-and-neck LMs reported favorable response. Only 1 patient (8.3%) encountered a peri-procedural complication. Percutaneous ethanol sclerotherapy of neck lymphangioma in our patient also reported favorable response with no complications. Invasive treatment for LMs should be personalized and dependent on the availability of experienced operators/ centers with appropriate volume in either primary excisional surgery or percutaneous sclerotherapy. Percutaneous ethanol sclerotherapy is an acceptable option with benefits of widespread availability and cost-effectiveness in our South-East Asia region. Limitations of our review are largely due to significant study heterogeneity.

BACKGROUND AND OBJECTIVES: Ischemic post-conditioning (PostC) has been demonstrated as a novel strategy to harness nature's protection against myocardial ischemia-reperfusion (I/R). Hypercholesterolemia (HC) has been reported to block the effect of PostC on the heart. Angiotensin II type-1 (AT1) modulators have shown benefits in myocardial ischemia. The present study investigates the effect of a novel inhibitor of AT1, azilsartan in PostC of the heart of normocholesterolemic (NC) and HC rats. MATERIALS AND METHODS: HC was induced by the administration of high-fat diet to the animals for eight weeks. Isolated Langendorff's perfused NC and HC rat hearts were exposed to global ischemia for 30 min and reperfusion for 120 min. I/R-injury had been assessed by cardiac hemodynamic parameters, myocardial infarct size, release of tumor necrosis factor-alpha troponin I, lactate dehydrogenase, creatine kinase, nitrite in coronary effluent, thiobarbituric acid reactive species, a reduced form of glutathione, superoxide anion, and left ventricle collagen content in normal and HC rat hearts. RESULTS: Azilsartan post-treatment and six episodes of PostC (10 sec each) afforded cardioprotection against I/R-injury in normal rat hearts. PostC protection against I/R-injury was abolished in HC rat hearts. Azilsartan prevented the HC-mediated impairment of the beneficial effects of PostC in I/R-induced myocardial injury, which was inhibited by L-N⁵-(1-Iminoethyl)ornithinehydrochloride, a potent inhibitor of endothelial nitric oxide synthase (eNOS). CONCLUSION: Azilsartan treatment has attenuated the HC-induced impairment of beneficial effects of PostC in I/R-injury of rat hearts, by specifically modulating eNOS. Azilsartan may be explored further in I/R-myocardial injury, both in NC and HC conditions, with or without PostC.
Angiotensin II ; Animals ; Collagen ; Creatine Kinase ; Diet, High-Fat ; Glutathione ; Heart ; Heart Ventricles ; Hemodynamics ; Hypercholesterolemia ; Ischemia ; Ischemic Postconditioning* ; L-Lactate Dehydrogenase ; Myocardial Infarction ; Myocardial Ischemia ; Nitric Oxide Synthase Type III ; Rats ; Reperfusion ; Reperfusion Injury ; Superoxides ; Troponin I ; Tumor Necrosis Factor-alpha

CD38 is a multifunctional enzyme expressed in a variety of mammalian tissues, its catalytic activity was involved in a wide range of physiological processes. Based on the reported inhibitor of human CD38 NADase, 33 purine derivatives were designed and synthesized. The biological activity assay showed that compounds 20 and 38 exhibited almost the same extent of inhibitory activities on human CD38 NADase as the lead compound H2. The results also revealed that small substituents at C-6 of purine ring gave no obvious effect on inhibitory activity, but phenylpropionyl moiety at N-2 could affect the binding mode of the compound with CD38. This study provides a reliable basis for future rational design of inhibitors for CD38.
ADP-ribosyl Cyclase 1 ; antagonists & inhibitors ; Enzyme Inhibitors ; chemical synthesis ; chemistry ; Humans ; Purines ; chemical synthesis ; chemistry

OBJECTIVETo evaluate the serological markers and biological marker in the diagnosis of hepatitis E infection in a rhesus monkey model.

METHODS86 rhesus monkeys had been infected with different doses of HEV. Hence, they were taken sequential blood samples at intervals up to 86 weeks for 4 hepatitis E virus (HEV) specific antibody assays (E2-IgM, E2-IgG, GL-IgG, and YES-IgG), and nucleic acid assay.

RESULTSAll the animals produced E2-IgG and all but one also produced E2-IgM and excreted the virus in stool, whereas positive rate of GL-IgG and YES IgG were low and correlated with virus level. Hepatitis occurred over a period of 4 weeks (between 3 an 7 weeks) after infection. Virological marker occurred mainly during incubation period and declined rapidly after onset of hepatitis. Seroconversion of E2-IgM occurred before onset of hepatitis in 70% monkeys and declined rapidly up to 50% of peak value after 4 weeks. E2-IgM seroconversion was closely paralleled by E2-IgG; however, E2-IgG persisted in all animals for the entire duration of experiment of up to 86 weeks. Production of GL-IgG and YES-IgG was delayed by one week after the E2 antibodies, these antibodies showed a transient occurrence and seroprevalence declined to 50% of the peak value over a period of 12 weeks.

CONCLUSIONE2-IgM might be used as a suitable acute hepatitis E marker, and E2-IgG as a suitable epidemiological marker. The seroconversion or titer elevation of GL-IgG and YES-IgG antibodies probably used to confirm the infection. The viral markers are optional for early diagnosis.

Alanine Transaminase ; blood ; Animals ; Biomarkers ; Genotype ; Hepatitis Antibodies ; blood ; Hepatitis E ; diagnosis ; Hepatitis E virus ; classification ; genetics ; immunology ; Immunoglobulin E ; blood ; Immunoglobulin M ; blood ; Macaca mulatta